A5045621877- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- COVID-19 Clinical Research Studies
- Pancreatitis Pathology and Treatment
- Sepsis Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Delphi Technique in Research
- Immunotherapy and Immune Responses
- Neonatal Health and Biochemistry
- Vitamin D Research Studies
- Epigenetics and DNA Methylation
- Psoriasis: Treatment and Pathogenesis
- Metastasis and carcinoma case studies
- COVID-19 diagnosis using AI
- Silicon Carbide Semiconductor Technologies
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Histone Deacetylase Inhibitors Research
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- COVID-19 and healthcare impacts
- Integrated Circuits and Semiconductor Failure Analysis
Chinese PLA General Hospital
2014-2023
University of Benin
2021
Hunan Provincial People's Hospital
2018-2021
Hunan Normal University
2018-2020
Abstract COVID‐19 has developed into a worldwide pandemic; early identification of severe illness is critical for controlling it and improving the prognosis patients with limited medical resources. The present study aimed to analyze characteristics identify biomarkers differential diagnosis prediction. In total, 27 consecutive 75 flu were retrospectively enrolled. Clinical parameters collected from electronic records. disease course was divided four stages: initial, progression, peak,...
The engineering of T lymphocytes to express chimeric antigen receptors (CARs) aims establish cell-mediated tumor immunity rapidly. In this study, we conducted a pilot clinical trial autologous or donor- derived cells genetically modified CAR targeting the B-cell CD19 harboring 4-1BB and CD3ζ moiety. All enrolled patients had relapsed chemotherapy-refractory lineage acute lymphocytic leukemia (B-ALL). Of nine patients, six definite extramedullary involvement, rate overall survival at 18 weeks...
Patients with relapsed or refractory non-Hodgkin lymphoma have a dismal prognosis. Chimeric Antigen Receptor (CAR)-modified T cells (CART cells) that targeted CD20 were effective in phase I clinical trial for patients advanced B-cell lymphomas. We performed IIa to further assess the safety and efficacy of administering autologous anti-CD20 CART (CART-20) CD20+ lymphoma. Eleven enrolled, seven underwent cytoreductive chemotherapy debulk tumors deplete lymphocytes before receiving T-cell...
The current clinical outcome for patients with metastatic pancreatic carcinoma (PC) remains poor. Epidermal growth factor receptor (EGFR) is detectable in PC, suggesting that EGFR a rational target PC. We conducted phase I trial to evaluate the safety and efficacy of autologous anti-EGFR chimeric antigen receptor-modified T (CAR T-EGFR) cells expression levels on tumor detected by immunohistochemistry were required be more than 50%. Sixteen enrolled received one three cycles CAR T-EGFR cell...
Recently, some global cases of 2019 novel coronavirus (COVID-19) pneumonia have been caused by second-or third-generation transmission the viral infection, resulting in no traceable epidemiological history.Owing to complications COVID-19 pneumonia, first symptom and imaging features patients can be very atypical early diagnosis infections remains a challenge.It would aid radiologists clinicians aware disease contribute prevention infected being missed.
Background Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined DNA demethylating decitabine, improves progression-free survival (PFS) cHL over camrelizumab alone. Methods This extended follow-up an ongoing randomized phase II trial analyzed PFS among enrolled from January 2017 through July 2018. Sixty-one who were clinically...
Aberrant DNA methylation is one of the main drivers tumor initiation and progression. The reversibility modulation makes it an attractive target for novel anticancer therapies. Clinical studies have demonstrated that high-dose decitabine, a hypomethylating agent, results in some clinical benefits patients with refractory advanced tumors; however, they are extremely toxic. Low doses decitabine minimize toxicity while potentially improving targeted effects hypomethylation. Based on these...
Abstract Purpose: Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients recalcitrant to PD-1 inhibitors and only minority achieves durable remission. Effective treatment regimens for those with relapsed/progressive cHL after single-agent anti-PD-1 are urgently needed. Anti-PD-1 combination the DNA-demethylating agent decitabine showed positive preliminary results our test cohort who were resistant...
Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in cell therapy, are expected to be used growing number cases. However, T-cell-associated toxicities can severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing studying clinical management these imperative. In...
Anti-CD19 chimeric antigen receptor-modified T (CAR-T-19) cells have emerged as a powerful targeted immunotherapy for B-cell lineage acute lymphoblastic leukemia with remarkable clinical response in recent trials. Nonetheless, few data are available on the subsequent monitoring and treatment of patients, especially those disease recurrence after CAR-T-19 cell infusion. Here, we analyzed three patients who survived our phase I trial were studied by means biomarkers reflecting persistence vivo...
Background: Adoptive immune cell transfer such as cytokine-induced killer (CIK) cells has become an important adjuvant approach in patients with tumours.
Purpose: To investigate the efficacy of a combination montelukast and vitamins A D drops in bronchial asthma children, its effect on quality life.Methods: Sixty children from June 2018 to 2020 were collected randomized into study group control (30 cases each group). Control received sodium (chewable tablets), while (capsules) plus. Clinical efficacy, lung function, serum inflammatory factors, life evaluated compared.Results: Compared with group, total treatment effectiveness was higher...
目的： 探讨肝内胆管结石相关的隐匿性胆管细胞癌的临床病理特征及治疗和预后情况。 方法： 收集湖南省人民医院2014—2019年诊断的28例肝内胆管结石相关的隐匿性胆管细胞癌患者的临床信息，分析其组织学形态、免疫表型特征及治疗和预后情况。 结果： 患者男性9例，女性19例，平均年龄59岁。临床、影像、大体检查均未见占位性病变。镜下观察，所有病例均可见高级别胆管上皮内肿瘤，其中13例可见浸润癌，浸润灶直径从0.2~1.2 cm不等。免疫组织化学显示癌胚抗原（CEA）及p53在高级别胆管上皮内肿瘤及浸润癌中均为阳性，Ki-67呈核阳性表达，在浸润癌区域阳性率5%~10%。25例随访1~51个月，6例死亡，余19例无复发和转移。 结论： 肝内胆管结石合并隐匿性胆管细胞癌是临床、影像及病理都易漏诊的病例，需要提高对其的临床及病理特征的认识，但其预后及治疗尚需更多病例进一步研究。.